Up to now, the total number of domestic Class II & III medical device product registrations within the validity period in China has reached 114,626.

By rapid development of China's immunoassay, the market share of chemiluminescence has gradually expanded. Immunoassay diagnosis was already the largest sub-field of the market in China, currently accounting for about 25%.

China's in vitro diagnosis began in the 1980s. In the past years, the Chinese IVD industry has been following the trend of national reform and opening up and has made great achievements in the world. At present, China's IVD has developed into a complete industrial chain from reagent instrument system to raw materials and from the domestic market to the global market. Its products have covered all the subdivided fields of the industry and become one of the countries with the most complete product lines of IVD industry in the world.

By the end of 2022, the total number of medical and health institutions nationwide reached 1,032,918, an increase of 1,983 compared to the previous year.

This report is jointly prepared by China Association of In-Vitro Diagnostics and In Vitro Diagnostics Society of China Association for Medical Devices Industry.

Cue Health Inc., a healthcare technology company, reported financial results for the fourth quarter and full-year 2022.

BioMérieux reported sales growth of 7 percent for the first half of 2021.The Marcy l'Etoile, France-based diagnostics firm reported total sales of €1.57 billion ($1.86 billion) for the six-month period ended June 30, 2020, up from €1.48 billion for the first half of 2020.